ClinicalTrials.gg
TerminatedNCT01564563Updated Feb 27, 2017

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

A Phase 2 interventional study of standard therapy and placebo in Acquired Bleeding Disorder and Bleeding During/Following Surgery, sponsored by Novo Nordisk A/S. Terminated at 7 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial enrollment was prematurely terminated due to excessively slow patient recruitment

From the registry’s dates

  • Registered 9 years 8 months after the study started (first participant enrolled Jun 2002, registered Mar 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.

02

Conditions studied

  • Acquired Bleeding Disorder
  • Bleeding During/Following Surgery
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have undergone a hematopoietic stem cell transplantation

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to trial product
  • Participation in other trials with unapproved drugs or trials with equal or similar objective
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
11 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: standard therapy · Drug: placebo

  • Experimental
    Low dose

    Drug: standard therapy · Drug: activated recombinant human factor VII

  • Experimental
    High dose

    Drug: standard therapy · Drug: activated recombinant human factor VII

Interventions

06

What researchers measure

Primary outcomes

  1. Effect on bleeding, defined as change in bleeding score

Secondary outcomes

  1. Transfusion requirements

  2. Bleeding evaluation

  3. Adverse events

  4. Changes in safety coagulation parameters

07

Study locations

7 sites
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novo Nordisk Investigational Site
    Duarte, California 91010, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21231-1000, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63110, United States
  • Novo Nordisk Investigational Site
    New York, New York 10021, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7035, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030-4009, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2002 to primary completion in Oct 2003, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2012
First posted
Mar 28, 2012
StartActual
Jun 28, 2002
Primary completionActual
Oct 27, 2003
CompletionActual
Oct 27, 2003
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01564563
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 28, 2012
Start date
Jun 28, 2002
Primary completion
Oct 27, 2003
Completion
Oct 27, 2003
Last update
Feb 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion